Mingshi Junzhi Secures Over RMB 50 Million in Series A Funding to Accelerate Product Registrations and Pipeline Development

Wuxi Marvel Stone Healthcare Secures Over RMB 50 Million in Series A FinancingRecently, Wuxi Marvel Stone Healthcare Co., Ltd., a pioneer in innovative miniaturized magnetic resonance imaging (MRI) technology, completed its Series A financing round of over RMB 50 million. The round was co-led by Shanghai Sunland Investment Management Co., Ltd. (Sunland Capital) and VINNO CAPITAL, with participation from Tibet Huaying Cci Capital Ltd (Huaying Investment) and other investors. The funds will be utilized for the innovative product applications, clinical trials, NMPA/FDA regulatory registrations, as well as market development and brand building for the company’s first two products: a mobile quantitative detector for fatty liver disease and a mid-field high-performance MRI system dedicated to neurosurgery. Meanwhile, the company will continue to expand its R&D team to ensure the steady progress of global innovative R&D for multiple disruptive miniaturized MRI products, including mobile, portable, and wearable systems. This financing marks another milestone for Wuxi Marvel Stone Healthcare, following its angel round which was exclusively invested by Huachuang Capital.

Wuxi Marvel Stone Healthcare Co., Ltd. was established in 2019 by a team of experienced business executives and young scientists, dedicated to driving disruptive innovative applications of magnetic resonance technology in the medical device sector. After two years of intensive research and development, the company has completed the development of a portable quantitative detector for fatty liver disease based on magnetic resonance principles and is currently conducting preclinical studies. The product’s detection accuracy and comprehensive evaluation capabilities have been widely recognized by multiple parties. Meanwhile, a series of non-traditional application scenarios developed on the company’s novel mid-to-low field superconducting magnetic resonance platform are gradually being implemented, with several new products expected to launch over the next one to two years.

Dr. Wu Ziyue, Founder of Wuxi Marvel Stone Healthcare Co., Ltd., stated that the company’s vision is to drive innovative applications of magnetic resonance (MR) technology in the medical field. Currently, the major pain points of MR are high examination costs and long waiting times. The company’s products aim to address these challenges associated with existing MR medical devices and make a breakthrough by extending beyond traditional radiology departments into clinical specialties. “Miniaturization and specialization” define our product positioning. Our vision is not to replace conventional MR systems in radiology departments, but to develop customized, miniaturized solutions tailored to the specific needs of specialized disciplines and diseases, thereby maximizing the creation of novel applications for this remarkable technology. The company will continue to deepen its focus on innovative MR applications, popularizing MR technology across more clinical departments and diverse usage scenarios.

Dr. Liu Daozhi, Partner at Sunland Capital, stated: “At Sunland, we focus on unmet clinical needs, emphasizing technology innovation driven by such needs, and we are optimistic about imaging solutions for clinical departments. The compact, portable MRI system developed by Wuxi Marvel Stone Healthcare represents a significant trend in MRI development. Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent type of liver disease, yet current diagnostic methods on the market all have limitations. The company’s compact device for quantitative assessment of hepatic steatosis is a globally innovative product, featuring low cost, accurate quantification, ease of operation, and no special configuration requirements, making it highly suitable for outpatient clinics and primary care hospitals. It addresses key clinical pain points in the treatment and management of NAFLD and offers substantial market potential. We expect that, under Dr. Wu’s leadership, Marvel Stone will bring its product to market as soon as possible to meet patients’ urgent needs.”

Qi Wei, Partner at VINNO CAPITAL, stated: "Magnetic Resonance Imaging (MRI) is regarded as the greatest medical imaging diagnostic tool of the 20th century. Since the earliest reports on the clinical application of low-field MRI, the industry has consistently sought to improve proton polarization by employing higher magnetic field strengths, thereby increasing available signals to generate superior images. To date, traditional MRI platform technologies have gradually matured, making further breakthroughs unlikely in the short term; nevertheless, significant limitations and challenges persist in the clinical use of MRI. Urgent issues such as operational costs, installation complexity, and safety need to be addressed. The core to overcoming these challenges—and indeed the future of MRI—lies in better leveraging diagnostic and interventional MRI under low magnetic field strengths (and at lower costs) to create value. We are delighted to see that Wuxi Marvel Stone Healthcare Co., Ltd. is dedicated to technological innovation and has achieved many groundbreaking advances in this direction. The company has developed a series of point-of-care testing (POCT) MRI products tailored to diverse clinical scenarios, many of which are first-of-their-kind in China or even globally. These innovations hold great promise for bringing new opportunities to the entire clinical MRI market!"

Yi Lifu, Founding Partner of Huaying Investment, stated: “Against the backdrop of precision medicine, medical imaging equipment, as one of the most critical medical devices, is inevitably moving towards miniaturization and specialization to precisely meet specialized clinical needs. However, despite being the imaging modality with the greatest potential, the application of magnetic resonance (MR) equipment has long been constrained by high development difficulties and excessive costs. Furthermore, the lack of relevant talent in China has made the specialization of MR equipment particularly challenging. Huaying Investment closely monitors the trends of miniaturization and specialization in medical imaging. The team at Wuxi Marvel Stone Healthcare Co., Ltd. possesses outstanding capabilities in MR system integration, algorithm optimization, and system design tailored to clinical needs. The company’s two upcoming innovative MR medical device products also hold significant market potential. Huaying Investment is honored and eager to support the company in promoting the widespread adoption of miniaturized, innovative MR equipment.”

Sunland Capital is a specialized fund focused on investing in the early and growth stages of the healthcare industry. With offices in Shanghai and Beijing, it targets high-growth sub-sectors such as biopharmaceuticals, medical devices (including in vitro diagnostics and gene technologies, minimally invasive interventional products, implantable devices, minimally invasive surgical instruments, and medical robots), and healthcare services. The firm has invested in nearly 40 leading healthcare companies, including Guoke Hengtai, Aupu Biotherapy, Deepwise Healthcare, Shengshi Taike, Baichen Medical, Zhishan Medical, Qianglian Zhichuang, Weike Medical, Ligetai, and Langhe Medical. Sunland Capital’s core team comprises founders of publicly listed healthcare companies, as well as professional financial and strategic investors. It provides value-added services to its portfolio companies in strategy formulation, talent acquisition, R&D, marketing, legal and regulatory compliance, mergers and acquisitions, IPOs, and industry association resources. Additionally, it assists portfolio companies in integrating advanced international technologies and establishing global operational concepts and standards, thereby fostering continuous innovation and development.

VINNO CAPITAL was founded by an investment management team with a global perspective and extensive industry expertise, specializing in early-stage venture capital investments in the ICT and medical device sectors. VINNO CAPITAL seeks cutting-edge technologies globally, with a primary focus on China, North America, and Israel, and prioritizes investments in technology-driven innovative enterprises. The VINNO team boasts rich industry experience and a proven track record in entrepreneurship, having invested in over 80 high-potential companies with strong innovation DNA, and has incubated a number of leading enterprises in their respective niche markets.

Huaying Investment, established in April 2016, is a professional investment institution focused on early-to-mid-stage projects at the intersection of “Health + Technology.” Adhering to the investment philosophy of “thinking like entrepreneurs,” the firm boasts extensive experience in angel and venture capital investments. Leveraging the industrial chain advantages of Huami Technology, a leading enterprise in smart wearables, the company directs its investments toward connecting technology with health, with deep strategic layouts in fields such as In Vitro Diagnostics (IVD), sports and wellness, and medical imaging. It has invested in over 50 sci-tech innovation projects in healthcare and smart living, with many portfolio companies growing into industry leaders in their respective niches.